Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250409) titled 'MK-1084 with MK-3475A in 1L KRAS G12C-mutant nonsquamous NSCLC' on Oct. 3.
Study Type: Interventional
Study Design:
randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose
Primary Sponsor: Fujita Tomoko
Condition:
Treatment-naive KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
Intervention:
Arm A:
- MK-1084 100 mg once daily oral
- MK-3475A 790 mg subcutaneous (SC) every 6 weeks (q6w)
Arm B:
- MK-3475A 790 mg SC q6w
- Carboplatin AUC5 mg/mL/min intravenous (IV) every 3 weeks (q3w) for 2 cycles (4 doses) OR Cisplatin 75 mg...